医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate Bolsters Custom Services Capabilities to Meet Growing Demand for Expert Analytical and Data Services

2016年02月24日 PM11:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & SAN FRANCISCO & TOKYO

Life science market intelligence firm Evaluate Ltd has strengthened its resources to support the continued growth of its project-based analytical and data services covering the pharma, biotech and medtech sectors. Paul Verdin joined Evaluate in 2015 to head up Custom Services and its dedicated analyst and technical team. Paul was previously at Thomson Reuters, where he played a key role in building the Life Sciences Professional Services organization. He is supported by Jon Moser, Services Delivery Lead. Jon has deep industry and Evaluate data expertise, having developed and shaped the EvaluatePharma® subscription service since 2004.

Evaluate’s Custom Services couple our deep industry expertise with our life science market intelligence, evaluation tools and forecasts. Frameworks and deliverables are designed in collaboration with our clients to maximize the value of our data, drive actionable insights, and help our clients solve their specific business problems”, said Paul Verdin.

Some examples of the types of services offered include:

  • Custom datasets based fully or partially on existing Evaluate content, aggregated, manipulated, and extended according to client needs
  • Analytical solutions combining Evaluate content, targeted external research, industry expertise, and our structured and tailored methodologies
  • Data management services to provide our clients with the right information, at the right time, and in the right format

To learn more about the Evaluate Custom Services please visit www.evaluate.com/customservices.

About Evaluate Ltd

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our subscription services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Evaluate Custom Services provides project-based analytical and data services. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluate.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP @epclinicaltrial, @epvantage.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160224005004/en/

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren,
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Trisha Rule, +1-858-230-4949
trule@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果